Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Chem Res Toxicol ; 27(8): 1344-58, 2014 Aug 18.
Artículo en Inglés | MEDLINE | ID: mdl-25014778

RESUMEN

Thiophene is a five-membered, sulfur-containing heteroaromatic ring commonly used as a building block in drugs. It is considered to be a structural alert, as its metabolism can lead to the formation of reactive metabolites. Thiophene S-oxides and thiophene epoxides are highly reactive electrophilic thiophene metabolites whose formation is cytochrome P450-dependent. These reactive thiophene-based metabolites are quite often responsible for drug-induced hepatotoxicity. Tienilic acid is an example of a thiophene-based drug that was withdrawn from the market after only a few months of use, due to severe cases of immune hepatitis. However, inclusion of the thiophene moiety in drugs does not necessarily result in toxic effects. The presence of other, less toxic metabolic pathways, as well as an effective detoxification system in our body, protects us from the bioactivation potential of the thiophene ring. Thus, the presence of a structural alert itself is insufficient to predict a compound's toxicity. The question therefore arises as to which factors significantly influence the toxicity of thiophene-containing drugs. There is no easy way to answer this question. However, the findings presented here indicate that, for a number of reasons, daily dose and alternative metabolic pathways are important factors when predicting toxicity and will therefore be discussed together with examples.


Asunto(s)
Tiofenos/química , Antidepresivos/química , Antidepresivos/uso terapéutico , Sistema Enzimático del Citocromo P-450/metabolismo , Depresión/tratamiento farmacológico , Clorhidrato de Duloxetina , Hepatitis/etiología , Humanos , Inhibidores de Agregación Plaquetaria/química , Inhibidores de Agregación Plaquetaria/metabolismo , Inhibidores de Agregación Plaquetaria/toxicidad , Tiofenos/metabolismo , Tiofenos/uso terapéutico , Tiofenos/toxicidad , Ticrinafeno/química , Ticrinafeno/metabolismo , Ticrinafeno/toxicidad
2.
Chemosphere ; 112: 362-9, 2014 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25048928

RESUMEN

The present study investigated and compared the estrogenic and androgenic activities of the three different classes of environmental pollutants and their metabolites using the XenoScreen XL YES/YAS assay, which has advantages compared with the original YES/YAS protocol. Contrary to the parent brominated flame retardants TBB and TBPH, which demonstrated no or very weak (anti)estrogenic or (anti)androgenic activities, their metabolites, TBBA and TBMEPH, exhibited anti-estrogenic (IC50 for TBBA=31.75 µM and IC50 for TBMEPH=0.265 µM) and anti-androgenic (IC50 for TBBA=73.95 µM and IC50 for TBMEPH=2.92 µM) activities. These results reveal that metabolism can enhance the anti-estrogenic and anti-androgenic effects of these two novel brominated flame retardants. Based on the activities of BPAF, BPF, BPA and MBP, we can conclude that the XenoScreen XL YES/YAS assay gives comparable results to the (anti)estrogenic or (anti)androgenic assays that are reported in the literature. For BPA, it was confirmed previously that the metabolite formed after an ipso-reaction (hydroxycumyl alcohol) exhibited higher estrogenic activity compared with the parent BPA, but this was not confirmed for BPAF and BPF ipso-metabolites, which were not active in the XenoScreen YES/YAS assay. Among the substituted BPA analogues, bis-GMA exhibited weak anti-estrogenic activity, BADGE demonstrated weak anti-estrogenic and anti-androgenic activities (IC50=13.73 µM), and the hydrolysed product BADGE·2H2O demonstrated no (anti)estrogenic or (anti)androgenic activities.


Asunto(s)
Bioensayo/métodos , Bromobenzoatos/toxicidad , Disruptores Endocrinos/metabolismo , Retardadores de Llama/metabolismo , Éteres Difenilos Halogenados/toxicidad , Fenoles/toxicidad , Saccharomyces cerevisiae/efectos de los fármacos , Antagonistas de Andrógenos/metabolismo , Antagonistas de Andrógenos/toxicidad , Bromobenzoatos/metabolismo , Ácidos Carboxílicos/metabolismo , Contaminantes Ambientales/metabolismo , Contaminantes Ambientales/toxicidad , Antagonistas de Estrógenos/metabolismo , Antagonistas de Estrógenos/toxicidad , Éteres Difenilos Halogenados/metabolismo
3.
Talanta ; 116: 887-93, 2013 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-24148490

RESUMEN

There are virtually no analytical methods that describe determination of vinblastine and other vinca alkaloids in tumour tissue, albeit quantitative data on tumour drug amount is essential for maximal benefit of a particular anticancer treatment. The analytical method presented herein uses state-of-the-art sample preparation, separation and detection techniques to allow sensitive and selective determination of vinblastine in tumour tissue. After cryogenic grinding and sonication, tumour suspensions were extracted by Oasis MAX solid phase extraction and analysed for vinblastine with ultra-high performance liquid chromatography coupled to positive electrospray ionisation-high resolution mass spectrometric detection. The developed analytical method quantifies vinblastine down to 23 ng/g tumour tissue and shows satisfactory linearity (r(2)>0.99), precision (1.1-8.2%), accuracy (98%) and high selectivity with almost complete absence of matrix effects. The proposed method was found suitable to follow vinblastine levels in mice tumours and could be used to support preclinical pharmacologic studies.


Asunto(s)
Antineoplásicos Fitogénicos/aislamiento & purificación , Fibrosarcoma/química , Neoplasias Cutáneas/química , Extracción en Fase Sólida/métodos , Vinblastina/aislamiento & purificación , Animales , Antineoplásicos Fitogénicos/administración & dosificación , Antineoplásicos Fitogénicos/farmacocinética , Calibración , Cromatografía Líquida de Alta Presión , Femenino , Fibrosarcoma/tratamiento farmacológico , Fibrosarcoma/patología , Límite de Detección , Masculino , Ratones , Neoplasias Experimentales , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/patología , Sonicación , Espectrometría de Masa por Ionización de Electrospray , Vinblastina/administración & dosificación , Vinblastina/farmacocinética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA